Hydroxyethyl starch macromolecules reduce myocardial reperfusion injury

Area of Science:

• Cardiology
• Pharmacology
• Experimental Medicine

Background:

• Myocardial reperfusion injury is a significant complication following ischemic events.
• Effective therapeutic strategies to mitigate reperfusion injury are crucial for improving patient outcomes.
• Hydroxyethyl starch (HES) is a colloid solution with potential benefits in managing fluid balance and tissue injury.

Purpose of the Study:

• To evaluate the efficacy of a specific fraction of hydroxyethyl starch (HES Pz) in reducing myocardial reperfusion injury.
• To compare the protective effects of HES Pz against Ringer's lactate and serum albumin in a preclinical model.
• To assess the impact of HES Pz on infarct size, myocardial water content, and ionic shifts post-ischemia.

Main Methods:

• A canine open-chest model was utilized, involving 1 hour of left anterior descending coronary artery occlusion followed by 24 hours of reperfusion.
• Three treatment groups received infusions of 5% blood volume: Ringer's lactate, serum albumin, and HES Pz.
• Infarct size, area at risk, myocardial water content, and potassium content differences were quantified and compared between groups.

Main Results:

• HES Pz significantly reduced the ratio of 24-hour infarct size to the area at risk (3%) compared to Ringer's lactate (19%) and albumin (16%).
• Myocardial water content was significantly lower in the HES Pz group (0.5%) versus Ringer's lactate (3%) and albumin (1%).
• Potassium content differences between injured and normal myocardium were less pronounced in animals treated with HES Pz.

Conclusions:

• HES Pz demonstrates significant efficacy in reducing myocardial ischemia reperfusion injury in a canine model.
• HES Pz offers superior protection against infarct expansion and edema compared to Ringer's lactate and albumin.
• These findings suggest HES Pz as a promising therapeutic agent for mitigating reperfusion injury in cardiac ischemia.